Skip to main content
Olema Pharmaceuticals, Inc. logo

Olema Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · OLMA ISIN · US68062P1066 US Manufacturing
Open in API
Filings indexed 506 across all filing types
Latest filing 2021-05-27 Director's Dealing
Country US United States of America
Listing US OLMA

About Olema Pharmaceuticals, Inc.

https://olema.com/

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers. The company concentrates on endocrine-driven diseases, with a primary emphasis on breast cancer. Its lead product candidate, palazestrant (OP-1250), is an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD). Palazestrant is under investigation in clinical trials as a potential treatment for patients with ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is advancing a pipeline of drug candidates with the goal of developing improved therapeutic options for cancer patients.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2021-05-27 English
Director's Dealing 2021
Director's Dealing
2021-05-20 English
10-Q
Interim / Quarterly Report Q1 2021
2021-05-11 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 11, 2021, reporting the financial results for the quarter ended March 31, 2021. It references a press release attached as Exhibit 99.1 containing the financial results. The document explicitly states that the information is furnished pursuant to Item 2.02 (Results of Operations and Financial Condition) and that the press release is incorporated by reference. The document length is 4090 characters, which is relatively short and mainly serves as an announcement of the earnings release rather than containing detailed financial statements or analysis itself. According to the 'Menu vs Meal' rule, such a document is an announcement of the earnings release, not the earnings release itself. Therefore, the appropriate classification is Earnings Release (ER).
2021-05-11 English
DEFA14A
Remuneration Information Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement related to shareholder voting matters. It includes details about the annual stockholders' meeting, proposals to be voted on, and instructions for voting. It is not the proxy statement itself but rather additional definitive materials related to the proxy. The document does not contain financial statements or detailed financial analysis, so it is not an Annual Report or Earnings Release. It is not a report publication announcement since it contains substantive proxy voting information. Therefore, the document fits the category of Remuneration Information (DEF 14A), which covers proxy statements and related materials concerning executive compensation and shareholder voting matters under Schedule 14A filings.
2021-04-27 English
DEF 14A
Proxy Solicitation & Information Statement
2021-04-27 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.